NeuroPace (NPCE) Common Equity (2020 - 2026)

NeuroPace has reported Common Equity for 7 years, with the latest figure at $11.9 million in Q2 2026.

• On a quarterly basis, Common Equity fell 38.87% year-over-year to $11.9 million in Q2 2026; TTM through Jun 2026 was $11.9 million, a 38.87% decrease from a year earlier, with the FY2025 full-year figure at $19.0 million, up 137.5% from the prior year.
• Common Equity was $11.9 million for Q2 2026 at NeuroPace, down from $14.5 million in the prior quarter.
• The five-year high for Common Equity was $62.8 million in Q1 2022, with the low at $8.0 million in Q4 2024.
• Average Common Equity over 5 years is $23.8 million, with a median of $19.2 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Common Equity jumped 140.16% in 2022, then sank 62.31% in 2023.
• Over 5 years, Common Equity stood at $34.8 million in 2022, then tumbled by 40.61% to $20.7 million in 2023, then plunged by 61.2% to $8.0 million in 2024, then jumped by 137.5% to $19.0 million in 2025, then plunged by 37.56% to $11.9 million in 2026.
• The last three Common Equity figures came in at $11.9 million (Q2 2026), $14.5 million (Q1 2026), and $19.0 million (Q4 2025), per Business Quant data.